Asthma – Landscape & Forecast – Disease Landscape & Forecast (G7)

The asthma therapy market consists of many well-established drugs, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva, Novartis’s Enerzair); oral drugs (e.g., montelukast); and biologics (e.g., GlaxoSmithKline’s Nucala, Sanofi / Regeneron’s Dupixent). The impending approval and launch of additional biological therapies, branded generic and generic inhaled drugs, and LABA/LAMA/ICS combination agents for asthma will further increase the competition in this already crowded market.

QUESTIONS ANSWERED

• What insights do thought leaders have on current inhaled branded, branded generic, and generic treatment options? What is the current and future market impact of branded generic and generic inhaled therapies?
• What are key opinion leaders’ perceptions of currently marketed asthma biologics (Nucala, Dupixent, Roche / Novartis’s Xolair, Teva’s Cinqair / Cinqaero, AstraZeneca’s Fasenra, AstraZeneca / Amgen’s Tezspire)? What drives physicians’ choice of a biologic for severe refractory asthma? How receptive are physicians to emerging agents, including GlaxoSmithKline’s depemokimab?
• How will the market evolve over the next 10 years given the launch of additional inhaled, oral, and biological products? What effect will the uptake of triple LABA/LAMA/ICS combination agents have on the sales and patient share of other inhaled therapies?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: ~20 country-specific interviews with thought leaders.

Epidemiology: Number of diagnosed and drug-treated prevalent cases of asthma; number of diagnosed and drug-treated prevalent cases of intermittent / mild persistent and moderate / severe persistent asthma.

Drug treatments: Coverage of key current and emerging therapies

PRODUCT DESCRIPTION